MoodRx cuts claim denials to under 0.5% ahead of ClaimsRevenue launch

MoodRx says it reduced its medical claim denial rate from more than 10% to less than 0.5% after a year of process changes and claims analysis. The company is turning that internal work into ClaimsRevenue, a new platform for independent medical and allied health practices launching Sept. 1.

Why it matters: - Independent healthcare practices often lack the revenue-cycle staffing and analytics resources of larger systems. - MoodRx's results are the basis for ClaimsRevenue, a platform built to help smaller practices reduce denials, payment delays and lost revenue. - The launch matters because professional claim reimbursement depends on more than filling out a form correctly.

What happened: - MoodRx said it lowered its medical claim denial rate from more than 10% to less than 0.5% over about a year. - The behavioral healthcare provider said the work became the foundation for ClaimsRevenue, a healthcare claims technology platform launching Sept. 1 for independent medical and allied health practices. - ClaimsRevenue officially launches to U.S. healthcare practices on Sept. 1, 2026.

The details: - The effort started with a closer look at MoodRx's revenue cycle and the factors tied to successful reimbursement. - The company broadened its review beyond required fields on professional claims. - MoodRx analyzed how clinical, billing, provider, payer and historical claims information interacted. - The company also studied previously adjudicated claims to find recurring patterns in payer outcomes. - Those lessons helped shape Claims Validator™, which reviews claims before submission. - They also informed ERA Analyzer™, which examines Electronic Remittance Advice data for recurring payer-response patterns. - MoodRx strengthened operational steps around claims, including payer participation, provider credentialing and patient eligibility verification before services were provided. - ClaimsRevenue is designed for professional medical claims in the CMS-1500/837P format. - The platform is aimed at primary care, physician specialties, medical and surgical practices, behavioral and mental health practices, physical therapy, occupational therapy and other medical and allied health provider offices. - ClaimsRevenue combines Claims Validator and ERA Analyzer to review claims before submission, study what happened after adjudication and use historical claims experience more effectively. - ClaimsRevenue.com offers more information and a product demonstration.

Between the lines: - The core idea is that denial prevention is less about one fix and more about understanding how multiple variables affect reimbursement. - Quazi framed the approach as roughly 20% operational discipline and 80% understanding a multivariable environment. - The product is built around the idea that past denials and adjustments can improve future claims, not just be corrected after the fact. - ClaimsRevenue does not guarantee that customers will match MoodRx's denial rate because every practice has different patients, payers, workflows and claims history.

What's next: - ClaimsRevenue will begin serving U.S. healthcare practices on Sept. 1, 2026. - The company is positioning the platform as a tool for practices that want earlier warning on claim problems and better use of adjudication history. - MoodRx said the product will continue to focus on identifying conditions that warrant additional review before submission.

The bottom line: - MoodRx turned an internal billing challenge into a software product built around one lesson: claim denials fall when practices look beyond isolated errors and manage the full reimbursement environment.